Viewing Study NCT00343421



Ignite Creation Date: 2024-05-05 @ 4:54 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00343421
Status: COMPLETED
Last Update Posted: 2016-06-03
First Post: 2006-06-21

Brief Title: Study to Compare Pediacel to Infanrix-IPVHib When Both Are Co-Administered With Prevenar in Infants and Toddlers
Sponsor: Sanofi Pasteur a Sanofi Company
Organization: Sanofi

Study Overview

Official Title: Immunogenicity and Safety of PEDIACEL a Combined Diphtheria Tetanus Five Component Acellular Pertussis Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine Adsorbed Compared to Infanrix-IPVHib When Both Vaccines Are Co-Administered With Prevenar to Infants and Toddlers at 2 3 4 and 12-18 Months of Age
Status: COMPLETED
Status Verified Date: 2016-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate safety and immunogenicity of Pediacel in infants and toddlers when given at 234 and 12-18 months of age

Primary Objectives

To compare the post-dose 3 immunogenicity of Pediacel to Infanrix-IPVHib when both are co-administered with Prevenar
To describe the post-dose 3 pertussis antibody responses

Secondary Objectives

To compare the post-dose 4 immunogenicity of Pediacel to Infanrix-IPVHib when both are co-administered with Prevenar
To describe the safety after each vaccination following co-administration with Prevenar
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None